SCHEMBL4813845

SCHEMBL4813845

COCCOCOc1[c]cccc1

nearest known ligand 0.33

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.33
CA2 P00918 1/20 0.32
MPO P05164 1/20 0.31
KDM4E B2RXH2 1/20 0.31
RECQL P46063 1/20 0.31
CTNNB1 P35222 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7779040 0.88 L3MBTL1 (0.37) TSHRCA2MPOKDM4ERECQL
SCHEMBL314763 0.85 TSHR (0.40) TSHRCA2MPO
SCHEMBL757705 0.83 PTPN1 (0.37) KDM4E
SCHEMBL8672408 0.81 LTA4H (0.43) TSHRKDM4ERECQL
SCHEMBL6132567 0.80 KCNA3 (0.35) TSHRKDM4E
SCHEMBL1143957 0.80 SMN1; SMN2 (0.38) TSHRKDM4E
SCHEMBL2499529 0.80 LTA4H (0.34)
SCHEMBL7283060 0.80 LTA4H (0.44) TSHRRECQL
SCHEMBL6132896 0.79 KDM4E (0.35) KDM4E
SCHEMBL9031404 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115181082-B Synthetic method of natural molecule Moracin M 江苏集萃分子工程研究院有限公司 2023-11-03 CN disclosed
CN-115181082-A Synthetic method of natural molecule Moracin M 江苏集萃分子工程研究院有限公司 2022-10-14 CN disclosed
US-7338941-B2 Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels DIAKRON PHARMACEUTICALS, INC. (US) 2008-03-04 US disclosed
EP-1501520-A1 PHARMACEUTICAL COMPOSITIONS FOR LOWERING BLOOD GLUCOSE AND BLOOD CHOLESTEROL LEVELS Diakron Pharmaceuticals, Inc. (US) 2005-02-02 EP disclosed
US-20040006128-A1 Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels Knobbe, Martens, Olson & Bear, LLP 2004-01-08 US disclosed
WO-2003094928-A1 PHARMACEUTICAL COMPOSITIONS FOR LOWERING BLOOD GLUCOSE AND BLOOD CHOLESTEROL LEVELS DIAKRON PHARMACEUTICALS, INC. (US) 2003-11-20 WO disclosed
EP-0551034-B1 Antibiotic cephalosporins having in position 7 a substituted benzyloxyimino radical HOECHST MARION ROUSSEL INC (FR) 2000-09-20 EP disclosed
EP-1016646-A1 Intermediates for the preparation of cephalosporines containing on the 7-position a substituted benzyloximino radical HOECHST MARION ROUSSEL (FR) 2000-07-05 EP disclosed
EP-0693496-A1 Novel cephalosporins having a substituted benzyloxyimino radical in position 7, process for their preparation and their use as medicaments ROUSSEL UCLAF (FR) 1996-01-24 EP disclosed
EP-0551034-A2 Cephalosporins having in position 7 a benzyloxyimino radical substitute, process for their preparation and their use as medicaments ROUSSEL UCLAF (FR) 1993-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006128-A1 Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels APOB, HDLBP, SERPINA6 TSHR 4369/4885CA2 2732/4885MPO 3520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.